Paper Details

  1. Home
  2. Paper Details

Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.

Author: HuangI-Hsin, HuangYu-Chen, LiuChe-Wei, WuPo-Chien

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review and meta-analysis investigated the association between topical calcineurin inhibitors (TCIs) and lymphoma risk. The findings indicate that TCI use significantly increases the risk of lymphoma, particularly non-Hodgkin lymphoma. This information is crucial for informing clinical decision-making and considering the potential risks associated with TCI use.
Paper Details　
Original Abstract of the Article :
The topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus have been used widely as corticosteroid-sparing agents in treating various cutaneous diseases. However, the association between TCIs and risk of malignancy remains controversial. By systematic review and meta-analysis, we aimed to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ddg.14527

データ提供：米国国立医学図書館（NLM）

The Link Between Topical Calcineurin Inhibitors and Lymphoma Risk

This research delves into the fascinating world of dermatology, specifically exploring the relationship between topical calcineurin inhibitors (TCIs) and the risk of developing lymphoma. The study, a systematic review and meta-analysis, employed a rigorous approach to analyze data from various cohort studies. The researchers aimed to understand whether using TCIs, like tacrolimus and pimecrolimus, increases the likelihood of developing lymphoma. Their findings revealed a significant increase in lymphoma risk among TCI users compared to those who did not use these medications.

TCIs and Lymphoma: A Closer Look

The analysis showed a 1.68 times higher risk of lymphoma for those using topical tacrolimus and a 1.40 times higher risk for those using topical pimecrolimus. Furthermore, subgroup analyses revealed that both tacrolimus and pimecrolimus were associated with a significantly increased risk of non-Hodgkin lymphoma, but not Hodgkin lymphoma. These findings suggest a more specific relationship between TCIs and a particular type of lymphoma.

Understanding the Implications for Patient Care

This research underscores the importance of considering the potential risks associated with TCI use. While TCIs are valuable tools in treating various skin conditions, the increased risk of lymphoma should be carefully weighed against their therapeutic benefits. It's crucial for healthcare providers to have open and transparent conversations with patients about these risks and weigh them against the potential benefits of treatment.

Dr.Camel's Conclusion

Just like a camel navigating a vast desert, this research provides valuable insights into the complexities of medical treatments. While TCIs offer a lifeline for individuals battling skin conditions, their use should be carefully considered in light of the potential risks. As with all medications, the benefits must be weighed against the potential drawbacks to ensure the well-being of patients.

Date :
  1. Date Completed 2021-09-28
  2. Date Revised 2021-09-28
Further Info :

Pubmed ID

34390192

DOI: Digital Object Identifier

10.1111/ddg.14527

Related Literature

Article Analysis
・Effects of pimecrolimus topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.